Overview

Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, two-arm, multicenter, exploratory study aimed at evaluating the efficacy and safety of the combination of etoposide, cytarabine and Pegfilgrastim (EAP regimen) for mobilizing hematopoietic stem cells in patients with newly diagnosed multiple myeloma (NDMM). A total of 99 NDMM patients will be enrolled and randomly assigned to receive either the EAP regimen or the GC regimen (cyclophosphamide+ G-CSF) to mobilize hematopoietic stem cells. Subsequently, the mobilization effects and adverse reactions of all patients will be observed and compared.
Phase:
PHASE3
Details
Lead Sponsor:
The Affiliated People's Hospital of Ningbo University
Collaborators:
Affiliated Hospital of Jiaxing University
Dongyang People's Hospital
First Affiliated Hospital of Wenzhou Medical University
First Affiliated Hospital of Zhejiang University
Huizhou Municipal Central Hospital
Jinhua Municipal Central Hospital
Jinhua People's Hospital
Ningbo Medical Center Lihuili Hospital
Second Affiliated Hospital of Wenzhou Medical University
Shaoxing People's Hospital
Shaoxing Second Hospital
Taizhou Hospital
Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
The Central Hospital of Lishui City
Zhejiang Provincial Tongde Hospital
Treatments:
Cyclophosphamide
Cytarabine
Etoposide
Granulocyte Colony-Stimulating Factor
pegfilgrastim
pegylated granulocyte colony-stimulating factor